GSK Secures Future in Hepatology with $2 Billion Acquisition of Efimosfermin from Boston Pharmaceuticals

GSK plc has entered into a $2 billion agreement with Boston Pharmaceuticals Inc. to acquire efimosfermin alfa, a phase III-ready treatment for steatotic liver disease, marking a si...